Over the past few years, I've been taking a hard look at mass screening programs. Educational surveys showed that almost 40% of participants believed screening to be preventive in that they would actually prevent prostate cancer - that they could stop it from happening, like a vaccine - by screening. Over 85% believed abnormal screening [...]
On June the 4th I reported on the SWOG-9346 study presented at the ASCO Meeting in Chicago (http://advancedprostatecancer.net/?p=3264). In the presentation by principal investigator, Maha Hussain, M.D., F.A.C.P., from the University of Michigan Comprehensive Cancer Center, Dr. Hussain reported that intermittent androgen-deprivation (IAD) therapy is not as good as continuous hormone therapy with regard to [...]
Earlier this year my mom was in a terrible care accident. She miraculously survived with multiple fractures. Were this to have happened to most women her age they would have been a pile of bone dust. In the hospital after the accident they set what bones they could and attached an external fixater on her [...]
In a study presented at ASCO, researchers found that the drug duloxetine (Cymbalta) can help to treat peripheral neuropathy, a painful side effect of chemotherapy using taxanes. Taxotere, the chemotherapy drug used to treat castrate resistant, advanced prostate cancer is a taxane. Peripheral neuropathy occurs when nerves in the body's peripheral nervous system (outside the [...]
The Early/Expanded Access Committee has announced the addition of a new site in Atlanta, Ga for the trial of MDV-3100. According to my sources, there will be even more sites added in the near future. The role of the trial is to provide expanded Access to MDV3100 and monitor its safety in men with progressive [...]